-
公开(公告)号：KR101558454B1
公开(公告)日：2015-10-06
申请号：KR1020130139833
申请日：2013-11-18
Applicant: 조선대학교산학협력단
Inventor： 최후균
IPC: A61K9/70 , A61K31/135 , A61P17/00
CPC classification number: A61K31/137 , A61K9/7038
Abstract: 본발명은유효성분으로서셀레질린또는그의약학적으로허용가능한염; 및점착제로서아크릴-고무하이브리드를포함하는약물-함유매트릭스층을포함하는경피흡수제제를제공한다.
-
公开(公告)号：KR1020150057134A
公开(公告)日：2015-05-28
申请号：KR1020130140080
申请日：2013-11-18
Applicant: 조선대학교산학협력단
Inventor： 최후균
IPC: A61K9/70 , A61K31/137 , A61K31/135 , A61P31/04
CPC classification number: A61K9/7053 , A61K31/137 , Y10S514/858
Abstract: 본발명은손발톱진균증치료를위한테르비나핀및 폴리이소부틸렌점착제로매트릭스를형성시킨약물-함유매트릭스층을포함한경피흡수제제로서, 장시간동안손발톱에부착되어지속적으로높은약물투과도를나타낼수 있는경피흡수제제를제공한다.
Abstract translation: 本发明涉及一种透皮药物，其包括由特比萘芬制成的含durg基质层和用于治疗甲真菌病的聚异丁烯粘合剂。 透皮药物附着在手指指甲和脚趾上，并持续提供高的药物渗透率。
-
公开(公告)号：KR1020130112413A
公开(公告)日：2013-10-14
申请号：KR1020120034779
申请日：2012-04-04
Applicant: 조선대학교산학협력단
Inventor： 최후균
IPC: A61K9/70 , A61K31/167 , A61K47/38
CPC classification number: A61K9/7038 , A61K31/167 , A61K47/10 , A61K47/30
Abstract: PURPOSE: A transdermal formulation is provided to remarkably enhance skin permeability of lidocaine and to suppress skin permeability of prilocaine in a proper level, thereby preventing side effects caused by excessive administration of prilocaine. CONSTITUTION: A transdermal formulation contains a mixture containing lidocaine or a salt thereof and prilocaine or a salt thereof mixed in a weight ratio of 5:1-1.4:1. The mixture is an eutetic mixture of lidocaine or the salt thereof and prilocaine or the salt thereof. The transdermal formulation comprises a support layer, a drug-containing matrix layer, and a release layer. [Reference numerals] (AA) Example 6; (BB) Comparative example 2
Abstract translation: 目的：提供透皮制剂，以显着增强利多卡因的皮肤渗透性，并将丙胺卡因的皮肤渗透性抑制在适当的水平，从而防止过量给予丙胺卡因引起的副作用。 构成：透皮制剂含有混合物，其混合物以重量比为5：1-1.4：1混合，所述混合物含有利多卡因或其盐和丙胺卡因或其盐。 混合物是利多卡因或其盐和丙胺卡因或其盐的混合物。 透皮制剂包括支持层，含药基质层和释放层。 （附图标记）（AA）实施例6; （BB）比较例2
-
公开(公告)号：KR101015546B1
公开(公告)日：2011-02-16
申请号：KR1020030086249
申请日：2003-12-01
Applicant: 조선대학교산학협력단
IPC: A61K9/70
Abstract: 본 발명은 (1) 기제로서 폴리스티렌을 구성성분으로 하는 비극성 공중합체;
(2) 항진균 활성성분으로서 시클로피록스 또는 시클로피록스 올라민염을 매트릭스층 총중량에 대하여 1~20 중량%;
(3) 결정화억제제를 매트릭스층 총중량에 대하여 0.1~10 중량%;
(4) 점착력부여제로서 로진 및 로진에스테르 유도체로 이루어진 군 중에서 선택된 1종 이상의 성분을 매트릭스층 총중량에 대하여 10~70 중량%; 그리고
(5) 가소제로서 탄화수소계 오일을 매트릭스층 총중량에 대하여 0.5~30 중량%를 포함하는 매트릭스층을 포함하는 손발톱 진균증 치료용 패취제 조성물에 관한 것이다.
시클로피록스, 패취제-
公开(公告)号：KR1020090101579A
公开(公告)日：2009-09-29
申请号：KR1020080026795
申请日：2008-03-24
Applicant: 조선대학교산학협력단
Inventor： 최후균
IPC: A61K9/70 , A61K31/445
CPC classification number: A61K9/7061 , A61K47/10 , A61K47/14
Abstract: PURPOSE: A transdermal preparation containing a pentanyl is provided to reduce inconvenience during relieving pain and enhance compliance of patient. CONSTITUTION: A transdermal preparation contains pentanyl as an active ingredient and one more penetration accelerator. The transdermal preparation also comprises acrylate polymer as an adhesive. The penetration accelerator is selected among polyglycery-3 olate (Plurol oleique cc497^®), polyethyleneglycol-20 amond glyceride (Crovol PK40^®), polyethyleneglycol-12 palm kernel glyceride (Crovol A40^®), isopropyl myristate (Crodamol IPM^®), isopropyl palmitate (Crodamol IPP^®), sorbitan mono olate (Span 80^®), oleyl alcohol (Oleyl alcohol^®), and polyethylene glycol 300(Polyethylene glycol 300^®).
Abstract translation: 目的：提供含有戊烷基的透皮制剂，以减轻疼痛缓解中的不便，增强患者的依从性。 构成：透皮制剂含有戊烷作为活性成分，另外还有一种渗透促进剂。 透皮制剂还包含作为粘合剂的丙烯酸酯聚合物。 渗透促进剂选自聚甘油-3酸酯（Plurol oleique cc497？），聚乙二醇-20 amond甘油酯（Crovol PK40？），聚乙二醇-12棕榈仁甘油酯（Crovol A40），肉豆蔻酸异丙酯（Crodamol IPM？ ），棕榈酸异丙酯（Crodamol IPP？），脱水山梨糖醇一月桂酸酯（Span 80），油醇（Oleyl alcohol）和聚乙二醇300（聚乙二醇300）。
-
Patent Agency Ranking
公开(公告)号：KR100835074B1
公开(公告)日：2008-06-03
申请号：KR1020060094007
申请日：2006-09-27
Applicant: 조선대학교산학협력단
Inventor： 최후균
IPC: A61K9/70
CPC classification number: A61K9/7061 , A61K31/5415
Abstract: 본 발명은 유효 성분으로서 멜록시캄을 포함하고 소르비탄 지방산 유도체, 폴리글리세릴 지방산 유도체, 폴리에틸렌글리콜의 식물유 에스테르, 폴리에칠렌글리콜 콘오일 글리세라이드, 폴리에칠렌글리콜 아몬드오일 글리세라이드로 구성된 그룹 중에서 선택된 1종 또는 2종 이상의 흡수촉진제를 함유하며 수산기를 가진 아크릴계 고분자와 관능기가 없는 아크릴계 고분자 중에서 선택된 1종 또는 2종 이상의 점착제로 구성된 경피 흡수 조성물과 이의 제조에 관한 것이다.
멜록시캄, 경피 흡수, 흡수 촉진제, 점착제-
公开(公告)号：KR1020070114896A
公开(公告)日：2007-12-05
申请号：KR1020060048521
申请日：2006-05-30
Applicant: 조선대학교산학협력단
IPC: C07D417/12 , A61K31/54
Abstract: Ethanolamine salts of meloxicam as non-steroidal anti-inflammatory drug are provided to reduce the time for attaining to the maximum blood concentration of meloxicam by improving release and absorption speeds of meloxicam, thereby rapidly relieving pain of a patient. An mono-, di- or tri-ethanolamine salt of meloxicam is represented by the formula(1), formula(2) or formula(3) and is prepared by dispersing or solubilizing meloxicam in ethanol, acetone or methanol, and adding monoethanol amine, diethanol amine or triethanol amine into the meloxicam solution. A pharmaceutical composition comprises the ethanolamine salt of meloxicam and is administered through mouse or injection.
Abstract translation: 提供美洛昔康的乙醇胺盐作为非甾体抗炎药，以通过改善美洛昔康的释放和吸收速度来减少获得美洛昔康最大血药浓度的时间，从而迅速缓解患者的疼痛。 美洛昔康的一，二或三乙醇胺盐由式（1），式（2）或式（3）表示，通过将美洛昔康分散或溶解在乙醇，丙酮或甲醇中制备，并加入单乙醇胺 ，二乙醇胺或三乙醇胺加入到美洛昔康溶液中。 药物组合物包含美洛昔康的乙醇胺盐，并通过小鼠或注射给药。
-
公开(公告)号：KR1020150064842A
公开(公告)日：2015-06-12
申请号：KR1020130149647
申请日：2013-12-04
Applicant: 조선대학교산학협력단
IPC: A61K9/70 , A61K31/4535 , A61P17/00
CPC classification number: A61K9/7061 , A61K31/4535
Abstract: 본발명은유효성분으로서케토티펜또는그의약학적으로허용되는염을포함한경피흡수제제에관한것으로, 보다구체적으로는케토티펜또는그의약학적으로허용되는염의피부투과속도를높일수 있는경피흡수용조성물로구성된매트릭스층을포함하는경피흡수제제에관한것이다.
Abstract translation: 本发明涉及包含酮替芬或酮替芬盐作为活性成分的透皮药物递送系统，更具体地涉及透皮药物递送系统，其包括由透皮组合物组成的基质层，其可以改善酮替芬或酮替芬盐的皮肤渗透速度 允许药物。 为了达到上述目的，本发明提供了一种透皮药物递送系统，其包括基质层，该基质层由酮替芬或被允许作为活性成分的酮替芬盐组成的透皮组合物和含有丙烯酸 - 橡胶杂化物或羟基作为粘合剂的基于丙烯酸的大分子组成。
-
公开(公告)号：KR1020130013157A
公开(公告)日：2013-02-06
申请号：KR1020110074618
申请日：2011-07-27
Applicant: 조선대학교산학협력단
IPC: A61K31/4709 , A61K31/47 , A61K47/48 , A61K47/38
CPC classification number: A61K31/4709 , A61K9/0053 , A61K9/10 , A61K47/14
Abstract: PURPOSE: A solid dispersion of cilostazol and polymethacrylate copolymers, and a pharmaceutical composition containing the same are provided to quickly release cilostazol and to reduce the dosage. CONSTITUTION: A solid dispersion with polymethacylate copolymers contains cilostazol. The copolymer is a copolymer of methacrylic acid and methyl methacrylate, a copolymer of methacrylic acid and ethyl acrylate, an ammonio methacrylate, or a copolymer of butyl methacrylate, (2-dimethyl aminoethyl)methacrylate, and methyl methacrylate. The solid dispersion additionally contains one or more polymers selected from a group consisting of hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, crospovidone, or a copolymer of vinylpyrrolidone and vinyl acetate. An oral pharmaceutical composition contains the solid dispersion and a pharmaceutically acceptable additive. [Reference numerals] (AA) Elution rate(%); (BB) Comparative embodiment 9; (CC) Comparative embodiment 10; (DD) Pletaal Tab.; (EE) Embodiment 7; (FF) Time(h)
Abstract translation: 目的：提供西洛他唑和聚甲基丙烯酸酯共聚物的固体分散体和含有它们的药物组合物以快速释放西洛他唑并减少剂量。 构成：含有聚甲基丙烯酸酯共聚物的固体分散体含有西洛他唑。 共聚物是甲基丙烯酸和甲基丙烯酸甲酯的共聚物，甲基丙烯酸和丙烯酸乙酯的共聚物，甲基丙烯酸铵，或甲基丙烯酸丁酯，（2-二甲基氨基乙基）甲基丙烯酸酯和甲基丙烯酸甲酯的共聚物。 固体分散体还含有一种或多种选自羟丙基甲基纤维素，聚乙烯吡咯烷酮，交聚维酮或乙烯基吡咯烷酮和乙酸乙烯酯的共聚物的聚合物。 口服药物组合物含有固体分散体和药学上可接受的添加剂。 （附图标记）（AA）洗脱率（％）; （BB）比较实施例9; （CC）比较实施例10; （DD）Pletaal Tab （EE）实施例7; （FF）时间（h）
-
公开(公告)号：KR1020120077004A
公开(公告)日：2012-07-10
申请号：KR1020100138804
申请日：2010-12-30
Applicant: 조선대학교산학협력단
IPC: A61K9/10 , A61K9/14 , A61K31/045 , A61K36/9066
CPC classification number: A61K47/34 , A61K9/10 , A61K31/12 , A61K47/44 , Y10S514/97 , Y10S514/975
Abstract: PURPOSE: A pharmaceutical composition or food composition containing curcurmin-containing solid dispersion is provided to enhance solubility and elution rate and to improve bioavailability. CONSTITUTION: A soild dispersion contains curcurmin and hydrophilic non-ionic surfactant with 10 or more of HLB value. The weight ratio of the curcurmin and hydrophilic non-ionic surfactant is 1:1-50. The solid dispersion is prepared by dissolving curcurmin and hydrophilic non-ionic surfactant in an organic solvent, or is prepared by drying the solution. The organic solvent is ethanol, methanol, dichloromethane, acetone, acetonitrile, or chloroform. The surfactant is polyethylene glycol, hydroxyl stearate, polyethylnene glycol hydrogenated castor oil, stearoyl macrogol glyceride, polyethylene glycol, sorbitan monooleate, or polyoxyethylene polyoxypropylene block copolymers. A pharmaceutical composition or food composition contains the solid dispersion.
Abstract translation: 目的：提供含有含Curcurmin的固体分散体的药物组合物或食品组合物，以提高溶解度和洗脱速度，提高生物利用度。 构成：含水分散体含有10份或更多HLB值的凝胶和亲水性非离子表面活性剂。 姜黄素和亲水性非离子表面活性剂的重量比为1:1-50。 通过将curcurmin和亲水性非离子表面活性剂溶解在有机溶剂中制备固体分散体，或通过干燥溶液制备。 有机溶剂为乙醇，甲醇，二氯甲烷，丙酮，乙腈或氯仿。 表面活性剂是聚乙二醇，硬脂酸羟基酯，聚乙烯乙二醇氢化蓖麻油，硬脂酰聚甘露糖甘油酯，聚乙二醇，脱水山梨醇单油酸酯或聚氧乙烯聚氧丙烯嵌段共聚物。 药物组合物或食物组合物含有固体分散体。
-
-
-
-
-
-
-
-
-
Search Results
36
records
(took 0.028 seconds)
